
Moleculin Biotech Secures Korean Patent for Annamycin Reconstitution Method
Moleculin Biotech, Inc. announced that South Korea's Ministry of Intellectual Property has granted a patent for the company's method of reconstituting liposomal Annamycin. This allowance expands Moleculin's international intellectual property portfolio, which now protects Annamycin across three complementary technology areas and over 20 jurisdictions. The company highlighted that this patent strengthens its global IP position as its pivotal Phase 3 MIRACLE trial for relapsed or refractory acute myeloid leukemia (AML) advances.
Key Highlights
- South Korea's Ministry of Intellectual Property granted a patent for Moleculin's method of reconstituting liposomal Annamycin.
- The patent allowance adds South Korea to Moleculin's international intellectual property estate for Annamycin.
- Moleculin's IP estate protects Annamycin across three complementary technology areas and more than 20 jurisdictions.
- The company is advancing its pivotal Phase 3 MIRACLE trial evaluating Annamycin for relapsed or refractory acute myeloid leukemia (AML).
Price Impact
More from MBRX
Moleculin Biotech Q3 Net Loss Shrinks to $6.5M; Secures Nasdaq Compliance Exception
Moleculin Biotech Secures Australian Patent for Annamycin Formulation
Moleculin Biotech: Annamycin Combo Shows Promise in Pancreatic Cancer Models